Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial.

Signal transduction and targeted therapy·2026

Same author

Orientation dependence of the magnetic phase diagram of Yb<sub>2</sub>Ti<sub>2</sub>O<sub>7</sub>.

Physical review. B·2026

Same author

Real-World Multicenter Study on the Effectiveness of Dolutegravir Plus Lamivudine in Treatment-Naive People Living with HIV with Baseline HIV-1 RNA > 500,000 Copies/mL.

Infectious diseases and therapy·2026

Same author

A large-scale retrospective analysis reveals the fungal pathogen spectrum across diverse clinical specimens using metagenomic next-generation sequencing.

Frontiers in cellular and infection microbiology·2026

Same author

The Global Burden and Trends of Premenopausal Breast Cancer by Modifiable Lifestyle Factors From 1990 to 2021 With Prediction Until 2039.

Global health, epidemiology and genomics·2026

Same author

Interfacial Electronic Modulation Redirects Anodic Radical Chemistry for Selective C─C Bond Cleavage in Electro-Oxidative Lignin Depolymerization.

Angewandte Chemie (International ed. in English)·2026

Search research articles

Related Experiment Video

Updated: Jun 26, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.

Yuxiang Lin¹, Guangyong Xu¹, Liangyu Li¹

¹Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

|May 17, 2024

Summary

Incretin-based drugs, used for type 2 diabetes, significantly lower prostate cancer risk by 35%. This includes glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, suggesting a potential preventive effect.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Related Experiment Videos

Last Updated: Jun 26, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Area of Science:

Endocrinology and Diabetes Research
Oncology and Cancer Prevention

Background:

Incretin-based medications are widely used for type 2 diabetes management.
A potential link between these antidiabetic medications and prostate cancer (PCa) incidence requires investigation.
Limited real-world data exists on the association between incretin-based drugs and PCa risk.

Purpose of the Study:

To evaluate the effect of incretin-based drugs on prostate cancer incidence.
To specifically assess the impact of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors on PCa risk.

Main Methods:

Systematic literature search of PubMed, Embase, and Cochrane Library databases up to September 2023.
Meta-analysis of data from 7 high-quality studies (2 RCTs, 5 cohort studies) involving 1,165,738 patients.
Quality assessment using the Cochrane Handbook and Newcastle-Ottawa Scale (NOS).

Main Results:

Incretin-based drugs were associated with a significant 35% reduction in prostate cancer risk (RR 0.17-0.49, P=0.0006).
Subgroup analysis showed GLP-1 receptor agonists reduced risk by 62% (RR 0.45-0.85, P=0.003).
DPP-4 inhibitors showed a trend towards risk reduction (RR 0.46-1.12, P=0.14).

Conclusions:

Incretin-based drugs are linked to a lower incidence of prostate cancer in patients with type 2 diabetes.
These antidiabetic medications may possess a protective effect against prostate cancer development.
Further research may elucidate the mechanisms behind this observed association.